NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with K i s of 2.5 µM and 1.3 µM, respectively. NU6027 is also a potent inhibitor of ATR and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner.

2011年7月5日 · NU6027 is a potent inhibitor of cellular ATR activity (IC 50 =6.7 μ M) and enhanced hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner.

2011年7月5日 · NU6027 inhibited ATR. We determined cellular ATR and CDK2 inhibition by NU6027, modulation of DNA damage-induced cell cycle arrest, repair by HR, enhancement of cytotoxic agents in cells

2011年7月26日 · NU6027 inhibits ATR, impairing G2/M arrest and homologous recombination thus increasing sensitivity to DNA-damaging agents and PARP inhibitors. It provides proof of concept data for clinical development of ATR inhibitors.

NU 6027 inhibits both CDK1 and CDK2 with IC 50 values of 2.9 and 2.2 µM, respectively. 1 It has been shown to inhibit cellular ataxia telangiectasia mutated and Rad3- related kinase activity (IC 50 = 6.7 µM) and impair G 2 /M arrest in various human cancer cells, potentiating the cytotoxic effects of DNA- damaging, anticancer agents such as cisp...

NU6027是一种有效的ATR/CDK抑制剂，抑制 CDK1/2， ATR 和 DNA-PK 时， Ki 分别为2.5 μM/1.3 μM， 0.4 μM和 2.2 μM ，进入细胞时比6-氨基嘌呤类抑制剂更容易。 NU6027抑制cdk1和cdk2效果比NU2058好。 NU6027 (100μM)抑制人类肿瘤细胞生长，平均GI50为10 μM。 NU6027作用于MCF7细胞，导致S期细胞数降低，而对G1或 G2/M期无影响。 [1] NU6027是有效的细胞内ATR活性抑制剂，作用于MCF7细胞，IC50为6.7 μM，作用于GM847KD细胞，IC50 …

ATR/CDK Inhibitor, NU6027 The ATR/CDK Inhibitor, NU6027, also referenced under CAS 220036-08-8, controls the biological activity of ATR/CDK. This small molecule/inhibitor is primarily used for Cancer applications.; CAS Number: 220036-08-8; Synonyms: ATR/CDK Inhibitor, NU6027,ATR Inhibitor, NU6027, 2,6-diamino-4-cyclohexyl-methyloxy-5-nitroso-pyrimidine, CDK2 Inhibitor, NU6027 at Sigma-Aldrich

2011年7月7日 · NU6027 is a potent inhibitor of cellular ATR activity (IC 50 =6.7 μ M) and enhanced hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner. NU6027 attenuated G2/M arrest following DNA damage, inhibited RAD51 focus formation and increased the cytotoxicity of the major classes of DNA-damaging anticancer cytotoxic therapy but not the ...

2011年7月26日 · Cell cycle effects and chemo- and radiopotentiation by NU6027 were determined in MCF7 cells and the role of mismatch repair and p53 was determined in isogenically matched ovarian cancer A2780...